Home » Newsletters » BioWorld Asia

BioWorld Asia

May 22, 2002

View Archived Issues

European Parliament Endorses Part Of Biotech Spending Plan

Rational Drug Discovery Approach Looks Promising For Alzheimer's

Genome Express Offers Bacterial Genomics Sequencing Service

Speedel Moves SPP 301 Into Phase II Pilot Studies

Celltech Picks Amgen To Help Advance Osteoporosis Program

HGS Gets Exclusive Development Rights To CAT Cancer Antibody

CeNeS Releases Positive Interim Results Of CNS5161 In Phase II

Enact Acquires Rights To Cytoxic, Prepares To File For Approvals

Other News To Note

Genset Chairman Resigns, Is Succeeded By Vasseur

Australian States Compete In Separate Biotech Initiatives

IDM Receives Approval For Ovarian Cancer Therapy Trial

Ark Delays Initial Public Offering Due To Unfavorable Conditions

LONDON - Ark Therapeutics Group plc postponed its initial public offering on the London Stock Market, blaming "unusually adverse market conditions." (BioWorld International) Read More